BCL2 and neoplasm: Multivariate analysis of clinical and pathological factors including IPI (defined by age, stage, serum LDH, performance status, and extranodal sites), sex, B-symptoms and tumor size, CD5+, Bcl-2+, and COO confirmed that CD5 expression independently predicted significantly poorer OS (P = .005) and PFS (P = .014) in DLBCL, in addition to the known unfavorable prognostic factors IPI >2 and Bcl-2+ (Table 3).